#Anti-CD226
LightNews LightNews
andrewedunn.bsky.social
Exclusive: Formation Bio raised a $372M Series D last year.

Later today, the New York biopharma will announce its first licensing deal since raising that money — bringing in a CD226 antibody from the Spanish biotech IMIDomics.

My latest for @endpts.com: endpoints.news/exclusive-fo...
Exclusive: Formation licenses first drug since $372M raise, eyes more deals in 2025
Formation Bio licenses first-in-class anti-CD226 antibody from IMIDomics for IBD treatment, marking first drug acquisition since $372M Series D raise in 2023.
endpoints.news
July 29, 2025 at 12:20 PM
endpts.com
Exclusive: Formation Bio has licensed its first drug since raising $372M — an anti-CD226 antibody from IMIDomics — and plans two more deals in 2025 as it builds out its pipeline.
Exclusive: Formation licenses first drug since $372M raise, eyes more deals in 2025
Formation Bio licenses first-in-class anti-CD226 antibody from IMIDomics for IBD treatment, marking first drug acquisition since $372M Series D raise in 2023.
endpoints.news
July 29, 2025 at 5:43 PM
newsen.bsky.social
Formation Bio Expands Its Immunology Portfolio with New Anti-CD226 License Agreement#USA#New_York#Formation_Bio#IMIDomics#Anti-CD226
Formation Bio Expands Its Immunology Portfolio with New Anti-CD226 License Agreement
Formation Bio has secured a license for IMIDomics' first-in-class anti-CD226 monoclonal antibody, targeting autoimmune diseases like ulcerative colitis, promising a new treatment avenue.
third-news.com
July 29, 2025 at 2:32 PM
www.pcb.ub.edu
#PCBCommunity |📢 La biotecnològica #IMIDomics signa un acord de llicència mundial amb la farmacèutica #FormationBio pel desenvolupament del seu programa #first-in-class d’anticòs monoclonal #anti-CD226, obrint la porta a noves opcions terapèutiques per les #MalaltiesAutoimmunes. 🛡️

👉 tuit.cat/0btiq
July 30, 2025 at 12:02 PM